🔎 Trials Near Me

Beranda › Kanker Gastrointestinal › Texas › Houston

Uji klinis Kanker Gastrointestinal di Houston, TX

21 studi untuk Kanker Gastrointestinal mencari peserta di lokasi sekitar Houston (dalam radius sekitar 30 mil). Buka studi untuk melihat kriteria peserta dan cara menghubungi tim studi.

Teks studi resmi (Bahasa Inggris)

Merekrut peserta untuk studi di sini? Tampilkan di bagian atas halaman ini — $99 selama 30 hari →

A Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)

Menerima pesertaFase 2
  • The University of Texas MD Anderson Cancer Center - Texas Medical Center, Houston
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 2 Okt 2026 · NCT06760819

Symbiotic-GI-03: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Metastatic Colorectal Cancer

Menerima pesertaFase 3
  • Oncology Consultants P.A., Houston
  • Oncology Consultants P.A., Houston
  • Texas Oncology - Gulf Coast, Houston
  • dan 7 lainnya
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 28 Sep 2026 · NCT07222800

A Study of IDRX-42 (GSK6042981) Versus (vs) Sunitinib in Participants With Gastrointestinal Stromal Tumors After Imatinib Therapy

Menerima pesertaFase 3
  • GSK Investigational Site, Houston
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 25 Sep 2026 · NCT07218926

Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors

Menerima pesertaFase 1/2
  • MD Anderson, Houston
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 22 Sep 2026 · NCT06128551

Study of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid Tumors

Menerima pesertaFase 1/2
  • Baylor College of Medicine, Houston
  • The University of Texas MD Anderson Cancer Center, Houston
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 22 Sep 2026 · NCT06445062

A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors

Menerima pesertaFase 1/2
  • The University of Texas, MD Anderson Cancer Center, Houston
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 11 Agu 2026 · NCT05592626

A Study to Test the Safety and Effectiveness of GSK5764227, Alone or With Other Treatments, in Participants With Advanced Gastrointestinal Cancers That Cannot be Surgically Removed (EMBOLD PanGI-201)

Menerima pesertaFase 1/2
  • GSK Investigational Site, Houston
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 3 Agu 2026 · NCT06885034

Evaluation of Portal Vein Stenting in Patients With Portal Vein Stenosis and Gastrointestinal Cancers

Menerima pesertaStudi observasional
  • M D Anderson Cancer Center, Houston
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 21 Jul 2026 · NCT04629677

Goals of Care Discussion for Patients With Advanced Lung and Gastrointestinal Cancer in the Emergency Department of a Comprehensive Cancer Center

Menerima peserta
  • MD Anderson Cancer Center, Houston
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 14 Jul 2026 · NCT06420206

A First in Human Study of PLT012 in Participants With Solid Tumor Cancers

Menerima pesertaFase 1
  • MD Anderson Cancer Center, Houston
  • NEXT Houston, Houston
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 7 Jul 2026 · NCT07337525

Telephone Support in Advanced Gastrointestinal Cancer

Menerima peserta
  • MD Anderson Cancer Center, Houston
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 6 Jul 2026 · NCT06532877

Improving Comprehensive Care of Cancer Patients

Menerima pesertaSukarelawan sehat diterima
  • Baylor College of Medicine, Houston
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 30 Jun 2026 · NCT05323409

BOLSTER: Learning New Skills to Thrive

Menerima peserta
  • The University of Texas MD Anderson Cancer Center, Houston
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 18 Jun 2026 · NCT06936878

Data Collection for the Assessment of Acute and Late Normal Tissue in Patients Treated With Proton Therapy

Menerima pesertaStudi observasional
  • M D Anderson Cancer Center, Houston
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 12 Jun 2026 · NCT00991094

Study of RMC-9805 in Participants With KRAS G12D-Mutant Solid Tumors

Menerima pesertaFase 1
  • University of Texas, MD Anderson Cancer Center, Houston
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 3 Jun 2026 · NCT06040541

A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements

Menerima pesertaFase 1/2
  • MD Anderson Cancer Center, Houston
Usia 12 ke atas · Semua jenis kelamin · Diperbarui 27 Mei 2026 · NCT03093116

Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS

Menerima pesertaFase 1/2
  • The University of Texas MD Anderson Cancer Center, Houston
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 15 Mei 2026 · NCT05379985

A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors

Menerima pesertaFase 1/2
  • MD Anderson Cancer Center, Houston
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 22 Apr 2026 · NCT07020221

Molecular Epidemiology of Biliary Tree Cancers

Menerima pesertaStudi observasional
  • M D Anderson Cancer Center, Houston
Semua usia · Semua jenis kelamin · Diperbarui 17 Apr 2026 · NCT05179486

Novel Rigidizing Overtube in Colonic Endoscopic Submucosal Dissection

Menerima peserta
  • Baylor College of Medicine, Houston
  • Baylor St. Lukes Medical Center (BSLMC), Houston
Usia 22 ke atas · Semua jenis kelamin · Diperbarui 24 Mar 2026 · NCT06134687

Traction vs. No Traction in Colonic ESD

Menerima peserta
  • Baylor College of Medicine, Houston
  • Baylor St. Lukes Medical Center (BSLMC), Houston
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 24 Mar 2026 · NCT06159634

Uji klinis Kanker Gastrointestinal di kota lain

Studi lain di Houston

Dari ClinicalTrials.gov, data diambil 5 Okt 2026. Setiap studi menetapkan kriteria kelayakannya sendiri; tim studi yang menentukan siapa yang bisa bergabung.